Valuation: Compass Therapeutics, Inc.

Market Cap 421M 370M 341M 315M 598M 40.35B 610M 4.1B 1.59B 19.75B 1.58B 1.55B 68.55B P/E 2026 *
-5.37x
P/E 2027 * -5.04x
Enterprise Value 271M 238M 220M 203M 385M 25.99B 393M 2.64B 1.03B 12.72B 1.02B 997M 44.15B EV / Sales 2026 *
-132x
EV / Sales 2027 * 11.5x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.86%
1 week+7.34%
Current month+6.85%
1 month+15.84%
3 months-56.67%
6 months-54.74%
Current year-56.42%
1 week 2.15
Extreme 2.15
2.35
1 month 1.88
Extreme 1.88
2.35
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 27/05/2024
Director of Finance/CFO 54 08/12/2024
Chief Tech/Sci/R&D Officer 50 31/12/2025
Director TitleAgeSince
Director/Board Member 65 31/12/2013
Director/Board Member 64 31/12/2014
Chairman 61 31/12/2014
Date Insider Type Main position Quantity % Market Cap.
04-28Buy

General Counsel

25,000 0.0139%
04-28Buy

Controller/Auditor

15,000 0.0083%
02-07Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+7.34%-11.70%-19.86% 421M
-0.88%-3.90%+70.54%+125.54% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+3.27%+8.91%+21.21%+486.76% 25.26B
-0.81%-0.42%-16.24%-12.47% 23.65B
+3.93%+3.35%+43.09%-2.47% 18.69B
-0.70%+0.24%+36.97%-26.48% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-0.92%+1.58%+35.79% - 14.26B
-1.70%+3.98%+28.96%+190.57% 14.1B
Average +0.29%+4.35%+49.66%+133.97% 23.98B
Weighted average by Cap. -0.19%+2.21%+57.42%+143.17%

Financials

2026 *2027 *
Net sales -2.06M -1.8M -1.67M -1.54M -2.92M -197M -2.98M -20.03M -7.78M -96.39M -7.73M -7.56M -335M 25.27M 22.16M 20.46M 18.91M 35.84M 2.42B 36.56M 246M 95.58M 1.18B 94.89M 92.81M 4.11B
Net income -82.44M -72.31M -66.75M -61.69M -117M -7.89B -119M -802M -312M -3.86B -310M -303M -13.41B -89.57M -78.56M -72.53M -67.02M -127M -8.58B -130M -872M -339M -4.2B -336M -329M -14.57B
Net Debt -150M -132M -121M -112M -213M -14.36B -217M -1.46B -567M -7.03B -563M -551M -24.4B -132M -116M -107M -98.77M -187M -12.64B -191M -1.28B -499M -6.19B -496M -485M -21.47B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
08/07/26 US$2.340 +0.86% 3,881,914
07/07/26 US$2.320 +1.31% 3,212,752
06/07/26 US$2.290 +0.88% 2,481,789
02/07/26 US$2.270 +4.13% 2,939,846
01/07/26 US$2.180 -0.46% 2,379,040
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.340USD
Average target price
8.500USD
Spread / Average Target
+263.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock